COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients with COVID-19, in addition to routine drug treatment, will receive 40 mg of nano curcumin capsules 4 times a day (one for breakfast, one for lunch, one for
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Laboratory-approved COVID-19 tests (2019-nCoV Real-Time RT-PCR) (preferably at a particular center or university-approved center) regardless of clinical manifestations and close contact history Signing a written consent form No simultaneous participation in other clinical trials
Exclusion criteria
Exclusion criteria: Pregnancy and lactation History of allergy to turmeric or curcumin products Smoking (more than 5 cigarettes a day) Patient connected to the ventilator Clinical evidence for respiratory failure at the time of hospitalization / admission (SaO2 = 90% or PaO2 <8 kPa) Having comorbidities (such as severe renal failure Glomerular filtration rate less than 30 ml / min, liver failure ,Congestive heart failure, or Chronic obstructive pulmonary disease) History of gallstones History of gastritis or active gastrointestinal ulcer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms. Timepoint: On a weekly basis, patients are examined clinically on days 1, 7, and 14. Method of measurement: Clinical examinations.;Immune cell balance. Timepoint: On a weekly basis, blood samples are taken from patients and patients are examined on days 1, 7 and 14. Method of measurement: Molecular experiments. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmin Reza Nikpoo
Bandare-abbas University of Medical Sciences
Outcome results
None listed